High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model

Naazneen Ibtehaj, Ruksana Huda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We investigated potential therapeutic effects of a conjugate of BAFF receptor specific-monoclonal antibody and short interference RNA in a mouse model of myasthenia gravis (EAMG). Whereas high-dose siRNA conjugate resulted in significant accumulation of Fas expressing CD19+/B220+ cells and concurrent expression of type 1 interferon in lymph nodes, low-dose conjugate did not induce FAS expression but caused marked BAFF receptor deficiency in lymph nodes that was further associated with improved MG symptoms. Unexpectedly, despite inhibiting BAFF receptor significantly in PBMCs and secondary lymphoid organs, conjugate treatment did not reduce the levels of autoantibody. Rather, at high dose, it caused robust increase in high affinity anti-AChR antibody and increased levels of serum IL10 and IL-4 cytokines. Our findings reveal a previously undocumented, dose dependent, immunomodulatory distant effect resulting from BAFF receptor specific mAb-siRNA conjugate treatment in an in vivo model of autoimmune disease.

Original languageEnglish (US)
Pages (from-to)122-130
Number of pages9
JournalClinical Immunology
Volume176
DOIs
StatePublished - Mar 1 2017

Fingerprint

B-Cell Activation Factor Receptor
Autoantibodies
Small Interfering RNA
B-Lymphocytes
Lymph Nodes
Serum
Interferon Type I
Myasthenia Gravis
Therapeutic Uses
RNA Interference
Interleukin-4
Interleukin-10
Autoimmune Diseases
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Cytokines

Keywords

  • AChR
  • Autoimmunity
  • BAFF receptor (BR)
  • EAMG
  • Fas
  • mAb-siRNA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model. / Ibtehaj, Naazneen; Huda, Ruksana.

In: Clinical Immunology, Vol. 176, 01.03.2017, p. 122-130.

Research output: Contribution to journalArticle

@article{8820f82e8c1541279a30bd0296e3b73b,
title = "High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model",
abstract = "We investigated potential therapeutic effects of a conjugate of BAFF receptor specific-monoclonal antibody and short interference RNA in a mouse model of myasthenia gravis (EAMG). Whereas high-dose siRNA conjugate resulted in significant accumulation of Fas expressing CD19+/B220+ cells and concurrent expression of type 1 interferon in lymph nodes, low-dose conjugate did not induce FAS expression but caused marked BAFF receptor deficiency in lymph nodes that was further associated with improved MG symptoms. Unexpectedly, despite inhibiting BAFF receptor significantly in PBMCs and secondary lymphoid organs, conjugate treatment did not reduce the levels of autoantibody. Rather, at high dose, it caused robust increase in high affinity anti-AChR antibody and increased levels of serum IL10 and IL-4 cytokines. Our findings reveal a previously undocumented, dose dependent, immunomodulatory distant effect resulting from BAFF receptor specific mAb-siRNA conjugate treatment in an in vivo model of autoimmune disease.",
keywords = "AChR, Autoimmunity, BAFF receptor (BR), EAMG, Fas, mAb-siRNA",
author = "Naazneen Ibtehaj and Ruksana Huda",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.clim.2017.01.005",
language = "English (US)",
volume = "176",
pages = "122--130",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model

AU - Ibtehaj, Naazneen

AU - Huda, Ruksana

PY - 2017/3/1

Y1 - 2017/3/1

N2 - We investigated potential therapeutic effects of a conjugate of BAFF receptor specific-monoclonal antibody and short interference RNA in a mouse model of myasthenia gravis (EAMG). Whereas high-dose siRNA conjugate resulted in significant accumulation of Fas expressing CD19+/B220+ cells and concurrent expression of type 1 interferon in lymph nodes, low-dose conjugate did not induce FAS expression but caused marked BAFF receptor deficiency in lymph nodes that was further associated with improved MG symptoms. Unexpectedly, despite inhibiting BAFF receptor significantly in PBMCs and secondary lymphoid organs, conjugate treatment did not reduce the levels of autoantibody. Rather, at high dose, it caused robust increase in high affinity anti-AChR antibody and increased levels of serum IL10 and IL-4 cytokines. Our findings reveal a previously undocumented, dose dependent, immunomodulatory distant effect resulting from BAFF receptor specific mAb-siRNA conjugate treatment in an in vivo model of autoimmune disease.

AB - We investigated potential therapeutic effects of a conjugate of BAFF receptor specific-monoclonal antibody and short interference RNA in a mouse model of myasthenia gravis (EAMG). Whereas high-dose siRNA conjugate resulted in significant accumulation of Fas expressing CD19+/B220+ cells and concurrent expression of type 1 interferon in lymph nodes, low-dose conjugate did not induce FAS expression but caused marked BAFF receptor deficiency in lymph nodes that was further associated with improved MG symptoms. Unexpectedly, despite inhibiting BAFF receptor significantly in PBMCs and secondary lymphoid organs, conjugate treatment did not reduce the levels of autoantibody. Rather, at high dose, it caused robust increase in high affinity anti-AChR antibody and increased levels of serum IL10 and IL-4 cytokines. Our findings reveal a previously undocumented, dose dependent, immunomodulatory distant effect resulting from BAFF receptor specific mAb-siRNA conjugate treatment in an in vivo model of autoimmune disease.

KW - AChR

KW - Autoimmunity

KW - BAFF receptor (BR)

KW - EAMG

KW - Fas

KW - mAb-siRNA

UR - http://www.scopus.com/inward/record.url?scp=85013750169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013750169&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2017.01.005

DO - 10.1016/j.clim.2017.01.005

M3 - Article

C2 - 28099879

AN - SCOPUS:85013750169

VL - 176

SP - 122

EP - 130

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

ER -